Effect of Enhanced Recovery After Surgery (ERAS) on C-reactive and Visceral Proteins

Effect of Enhanced Recovery After Surgery (ERAS) on C-reactive and Visceral Proteins in Patients With Advanced Gastric Cancer

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02348229

Acronym

ERASAG

Enrollment

149

Registered

2015-01-28

Start date

2013-09-30

Completion date

2014-10-31

Last updated

2015-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Keywords

Enhanced recovery after surgery, laparoscopic gastrectomy, advanced gastric cancer, C-reactive,visceral proteins

Brief summary

The investigators designed a prospective randomized, controlled clinical trial then recruited 149 consecutive advanced gastric cancer patients. Further divided into a ERAS group (n=73) and a conventional pathway group (n=76). Surgical technique in both groups was same laparoscopic-assisted gastrectomy with D2 lymphadenectomy. Compared outcomes included clinical parameters and serum indicators.

Detailed description

Enhanced recovery after surgery combined with laparoscopic-assisted gastrectomy was successfully carried out in this study. Recovery parameters such as the length of time to return to normal diet,mean hospital stay (d) were recorded.

Interventions

PROCEDUREERAS protocols

Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery

PROCEDUREconventional pathway group

No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Age 18-75 years old 2. Diagnosis confirmed by the endoscopic biopsy and total-body CT scan 3. No history of the chronic renal disease ,chronic liver disease, cardiopulmonary dysfunction, ASA score≦3 4. No neoadjuvant chemotherapy and radiotherapy 5. No digestive obstruction and distant metastasis

Exclusion criteria

1. Conversion to open gastrectomy 2. A large amount of bleeding leading(\>500ml) 3. Patients withdrew their consent

Design outcomes

Primary

Measure	Time frame
Compartition of postoperative hospital stay	up to 30 days after the operation

Secondary

Measure	Time frame	Description
Change from baseline in C-Reactive Protein( CRP) and visceral proteins level	baseline and 5 days	1day before and 1-5days after operation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026